Oric Pharmaceuticals Inc (ORIC)
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies designed to address resistance mechanisms in cancer. The company’s pipeline includes enozertinib, formerly ORIC-114, an orally available, brain-penetrant irreversible inhibitor being studied in Phase 1b for targets tied to EGFR exon 20 and HER2 exon 20 mutations, and rinzimetostat, formerly ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 in Phase 1b development for prostate cancer. ORIC also has clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to evaluate ORIC-944 in combination with Nubeqa and Erleada, respectively. Incorporated in 2014, the company is headquartered in South San Francisco, California, and its common stock trades on the NASDAQ under the symbol ORIC.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ORIC
|
$8.24
|
-23.9% Downside
|
Overvalued
|
$20.29
|
87.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-8.3x
|
2.7x
|
—
|
1.079 B
|
715.4 M
|
0.6%
|
79.9%
|
27.8
|
—
|
82.2%
|
